In a phase II trial conducted in 25 pretreated patients with RET+ lung adenocarcinoma, lenvatinib (24 mg once daily) showed 16% in ORR (95% CI: 4.5–36.1), with no significant differences between patients with the KIF5B–RET fusion variant and the CCDC6–RET fusion variant [37]. The gene discussed is RET; the disease is lung adenocarcinoma.